Novo Nordisk A/S — Wall Street Analyst Estimates & Price Targets

NVO

NYSEHealthcareDrug Manufacturers - GeneralCIK 0000353278novonordisk.comAbout NVO

Last close · Oct 30, 202640.00+0.86 (+2.20%)

The analysts at a glance

close of Oct 30, 2026

$40.00median of 3 firms' latest targets, level with the last close of $40.00

Firms with a target · last 90 days: 3
Lowest – highest target: $40.00 – $47.00
Current grades of 6 firms: positive / neutral / negative: 0 / 5 / 1
Upgrades / downgrades · 12 months: 0 / 5
Consensus revenue growth · next 3 FY: +2% a year

Price and published targets

daily close, 12 months · each dot a target, a firm's latest darker

Each firm's latest target

last 90 days · 3 firms

Date	Firm	Target	Previous	Change	Vs price then	Vs price now
2026-10-12	BMO Capital	$40.00	$47.00	▼ 15%	+4%	+0%
2026-09-11	Morgan Stanley	$40.00	$42.00	▼ 5%	-9%	+0%
2026-08-12	Berenberg Bank	$47.00	—	—	+0%	+18%

Current grades

each firm's latest · 6 firms

As of	Firm	Grade
2026-10-12	BMO Capital	“Market Perform”
2026-09-11	Morgan Stanley	“Underweight”
2026-03-02	Goldman Sachs	“Neutral”
2026-02-24	J.P. Morgan	“Neutral”
2025-12-08	Argus Research	“Hold”
2025-11-24	HSBC	“Hold”

Grade changes

last 24 months · 13

Date	Firm	Grade
2026-09-11	Morgan Stanley	“Equal Weight” → “Underweight” downgrade
2026-03-02	Goldman Sachs	“Buy” → “Neutral” downgrade
2026-02-24	J.P. Morgan	“Overweight” → “Neutral” downgrade
2025-12-08	Argus Research	“Buy” → “Hold” downgrade
2025-11-24	HSBC	“Buy” → “Hold” downgrade
2025-10-02	HSBC	“Hold” → “Buy” upgrade
2025-09-29	Morgan Stanley	“Equal Weight” → “Underweight” downgrade
2025-09-17	Berenberg	“Hold” → “Buy” upgrade
2025-08-05	UBS	“Buy” → “Neutral” downgrade
2025-07-31	HSBC	“Buy” → “Hold” downgrade

50 more

2025-07-30	Barclays	“Overweight” → “Equal Weight” downgrade
2025-04-17	BMO Capital	“Outperform” → “Market Perform” downgrade
2025-01-08	UBS	“Sell” → “Buy” upgrade
2022-06-28	UBS	“Neutral” → “Sell” downgrade
2022-06-07	J.P. Morgan	“Neutral” → “Overweight” upgrade
2022-05-31	Guggenheim	“Neutral” → “Buy” upgrade
2022-03-16	Deutsche Bank	“Hold” → “Buy” upgrade
2022-01-25	Liberum	“Hold” → “Sell” downgrade
2021-12-20	J.P. Morgan	“Overweight” → “Neutral” downgrade
2020-09-02	JMP Securities	“Market Outperform” → “Outperform” revised
2020-07-22	Bank of America	“Neutral” → “Buy” upgrade
2020-06-15	Credit Suisse	“Neutral” → “Outperform” upgrade
2020-05-20	Bank of America	“Buy” → “Neutral” downgrade
2020-05-19	Credit Suisse	“Outperform” → “Neutral” downgrade
2020-01-03	Guggenheim Securities	“Buy” → “Neutral” downgrade
2019-11-18	UBS	“Buy” → “Neutral” downgrade
2019-11-18	Barclays	“Equal Weight” → “Overweight” upgrade
2019-09-17	Citigroup	“Neutral” → “Buy” upgrade
2019-08-30	Jefferies	“Hold” → “Underperform” downgrade
2019-06-20	Deutsche Bank	“Buy” → “Hold” downgrade
2019-06-11	Barclays	“Underweight” → “Equal Weight” upgrade
2019-04-29	Credit Suisse	“Neutral” → “Outperform” upgrade
2018-11-19	J.P. Morgan	“Neutral” → “Overweight” upgrade
2018-10-08	Bank of America	“Buy” → “Neutral” downgrade
2017-12-29	J.P. Morgan	“Underweight” → “Neutral” upgrade
2017-12-06	Bank of America	“Neutral” → “Buy” upgrade
2017-12-01	Morgan Stanley	“Equal Weight” → “Overweight” upgrade
2017-09-06	Bank of America	“Underperform” → “Neutral” upgrade
2016-12-06	UBS	“Sell” → “Buy” upgrade
2016-10-31	Citigroup	“Buy” → “Neutral” downgrade
2016-10-28	Bank of America	“Neutral” → “Underperform” downgrade
2016-09-14	BNP Paribas Exane	“Neutral” → “Outperform” upgrade
2016-09-12	Deutsche Bank	“Hold” → “Buy” upgrade
2016-09-09	J.P. Morgan	“Outperform” → “Neutral” downgrade
2016-08-31	HSBC	“Reduce” → “Hold” upgrade
2016-08-08	Bank of America	“Buy” → “Neutral” downgrade
2016-02-08	UBS	“Neutral” → “Sell” downgrade
2016-01-26	Oddo BHF	“Neutral” → “Buy” upgrade
2015-10-19	Jyske Bank	“Buy” → “Strong Buy” upgrade
2015-08-28	Leerink Partners	“Market Perform” → “Perform” revised
2015-01-28	Commerzbank	“Buy” → “Hold” downgrade
2014-02-25	Bank of America	“Neutral” → “Buy” upgrade
2014-02-24	J.P. Morgan	“Underweight” → “Overweight” upgrade
2014-01-31	Swedbank	“Neutral” → “Buy” upgrade
2013-11-01	Swedbank	“Buy” → “Neutral” downgrade
2013-09-16	Barclays	“Underweight” → “Overweight” upgrade
2013-09-06	Swedbank	“Strong Buy” → “Buy” downgrade
2013-06-24	Baader Helvea	“Accumulate” → “Buy” revised
2013-06-24	Helvea-Baader	“Accumulate” → “Buy” revised
2013-06-19	BNP Paribas Exane	“Neutral” → “Underperform” downgrade

Consensus estimates

revenue and EPS by fiscal year · reported years marked

FY	Revenue	YoY	EPS	YoY	Revenue range	EPS range	Analysts
2023reported	$232.3B	+31%	$18.62	+52%	est. $226.8B+2%	est. $18.11	3
2024reported	$290.4B	+25%	$22.63	+22%	est. $286.1B+1%	est. $22.58	13
2025reported	$309.1B	+6%	$23.03	+2%	est. $308.0B+0%	est. $23.54	14
2026	$304.4B	-2%	$22.25	-5%	$296.3B–$317.5B	$21.34–$23.62	16
2027	$309.6B	+2%	$22.10	-1%	$304.4B–$317.5B	$20.42–$23.27	15
2028	$328.7B	+6%	$23.88	+8%	$313.3B–$352.5B	$22.43–$26.14	6
2029	$355.0B	+8%	$26.77	+12%	$338.5B–$380.8B	$25.15–$29.30	10
2030	$372.2B	+5%	$29.00	+8%	$354.9B–$399.2B	$27.24–$31.74	7

A reported year shows the company's figures, with the consensus beside it (revenue against it in %). Reported EPS is GAAP diluted; the analysts' EPS usually leaves items such as stock compensation out, so the two are not like for like. Faded: a year the valuation models do not read — they read the first 3, and a later one only while 10 or more analysts cover every year up to it — or one under 5 analysts.

Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.